Similarly, aberrant HDAC expression in lymphoma [47] argues for the use of HDACIs in this disorder, and in fact these agents have received approval or orphan drug status in CTCL/PTCL and some forms of DLBCL [48]. This evidence concerns the gene HDAC9 and diffuse large B-cell lymphoma.